Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Zander Therapeutics, Inc | zander012220form8k.htm |
| EX-99.1 - EXHIBIT 99.1 - Zander Therapeutics, Inc | ex99_1.htm |
Exhibit 99.2
Sublease Termination Agreement
Effective January 22, 2020 at 1 pm Pacific Standard Time, BST Partners Inc. (Sublessor / Sublandlord) hereby terminates the subleases with Sublessees / Subtenants: Regen BioPharma Inc. (along with its wholly owned subsidiary KCL Therapeutics Inc.) and Zander Therapeutics Inc.
Sublessees / Subtenants Regen BioPharma Inc. (along with its wholly owned subsidiary KCL Therapeutics Inc.) and Zander Therapeutics Inc. consent and agree to termination of subleases effective January 22, 2020 at 1 pm Pacific Standard Time.
Signed in agreement with the above on this 20th day of January, 2020:
| David R. Koos | David R. Koos | David R. Koos | ||
| Chairman & CEO | Chairman & CEO | Chairman & CEO | ||
| BST Partners Inc. | Regen BioPharma Inc. | Zander Therapeutics Inc. | ||
| (and KCL Therapeutics Inc.) | ||||
| /s/David R. Koos | /s/ David R. Koos | /s/ David R. Koos | ||
| Date:1/20/2020 | Date: 1/20/2020 | Date:1/20/2020 |